{"id":"W4417530895","doi":"10.1016/j.esmorc.2025.100055","title":"IMMUNOSARC2 (COHORT 7A): A SPANISH SARCOMA GROUP (GEIS) PHASE IB TRIAL OF EPIRUBICIN AND IFOSFAMIDE PLUS NIVOLUMAB IN FIRST LINE OF ADVANCED UNDIFFERENTIATED PLEOMORPHIC SARCOMA (UPS)","year":2025,"lang":"en","type":"article","venue":"ESMO rare cancers.","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Duke Cancer Institute; National Cancer Institute; Knight Cancer Institute, Oregon Health and Science University; University of Texas MD Anderson Cancer Center; University of California, Irvine; USC Norris Comprehensive Cancer Center; McGill University Health Centre; Huntsman Cancer Institute; McGill University; Royal Marsden NHS Foundation Trust; Medical Center, University of Pittsburgh; University of Pittsburgh; Washington University in St. Louis; Moffitt Cancer Center; Centre Hospitalier Universitaire de Bordeaux; University of Southern California; National Institutes of Health; Ohio State University; Memorial Sloan-Kettering Cancer Center; Children's Hospital of Philadelphia","keywords":"Nivolumab; Ifosfamide; Epirubicin; Sarcoma; First line; Chemotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003038421,0.0003692691,0.001256459,0.0005436125,0.00009838916,0.00001629491,0.0002336632,0.0001940184,0.0002878234],"category_scores_gemma":[0.0004988987,0.0003409772,0.0001951836,0.0008102265,0.0003451445,0.0001381496,0.0001647334,0.0004237319,0.000003887915],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00081694,"about_ca_system_score_gemma":0.0007132813,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009569853,"about_ca_topic_score_gemma":0.00587643,"domain_scores_codex":[0.9972021,0.0001655131,0.0009092599,0.0006014639,0.0005316135,0.0005900539],"domain_scores_gemma":[0.9982678,0.0003747737,0.0002817373,0.0006653774,0.0001891211,0.0002212478],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.3631703,0.005538309,0.4936384,0.002692387,0.00309893,0.001314368,0.0009471375,0.000151321,0.0249856,0.0004314617,0.0007882977,0.1032435],"study_design_scores_gemma":[0.4650464,0.005032033,0.5030646,0.002155463,0.0004386372,0.00002500871,0.0002937957,0.003350575,0.01866685,0.0002673973,0.001267507,0.0003916897],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9923073,0.003454718,0.0001618804,0.000419182,0.0002789595,0.002619923,0.0002563859,0.00004850329,0.0004531184],"genre_scores_gemma":[0.9962707,0.002144868,0.0002428938,0.00007572161,0.00006874132,0.0002301025,0.0004654557,0.0000411568,0.0004603279],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1028518,"threshold_uncertainty_score":0.9999042,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02086258826529606,"score_gpt":0.3186337084991464,"score_spread":0.2977711202338503,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}